[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604555":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":68,"collaborators":20,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":20,"enrollmentInfo":80,"targetDuration":20,"studyType":83,"phases":84,"briefSummary":87,"conditions":88,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},{"fullName":5,"class":6},"OneCarbon","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm dose","EXPERIMENTAL","Phase 1a (escalation) Single arm dose escalation of TH9619 as monotherapy. Phase 1b (expansion) Single arm dose expansion of TH9619 as monotherapy in selected tumor types.",[13],"Drug: TH9619",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TH9619","Phase 1a - DOSE ESCALATION\n\nDescription:\n\nSingle arm dose escalation of TH9619 as monotherapy.\n\nPhase 1b - DOSE EXPANSION\n\nDescription:\n\nSingle arm dose expansion of TH9619 as monotherapy in selected tumor types. The objectives and endpoints for the expansion cohort(s) will be defined in a protocol amendment, once data from Phase 1a are available.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Victoria Moody","CONTACT","+46708555182","victoria.moody@one-carbon.com",[28,40,50,58],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":20},"Institut Gustave Roussy","RECRUITING","Villejuif","France","FR",{"type":35,"coordinates":36},"Point",[37,38],2.35992,48.7939,{"lat":38,"lon":37},{"facility":41,"status":30,"city":42,"state":20,"zip":20,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":49,"contacts":20},"Vall D Hebron Institute Of Oncology","Barcelona","Spain","ES",{"type":35,"coordinates":46},[47,48],2.15899,41.38879,{"lat":48,"lon":47},{"facility":51,"status":30,"city":52,"state":20,"zip":20,"country":43,"countryCode":44,"cosmosGeoPoint":53,"geoPoint":57,"contacts":20},"Hospital Universitario Fundacion Jimenez Diaz","Madrid",{"type":35,"coordinates":54},[55,56],-3.70256,40.4165,{"lat":56,"lon":55},{"facility":59,"status":30,"city":60,"state":20,"zip":20,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":20},"Newcastle University","Newcastle upon Tyne","United Kingdom","UK",{"type":35,"coordinates":64},[65,66],-1.61396,54.97328,{"lat":66,"lon":65},{"type":69,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100604555","phase-1-phase-12-study-to-evaluate-th9619-in-the-treatment-of-advanced-solid-tumors-100604555",false,"NCT07151040","Phase 1\u002F2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","A First-in-human, Phase 1\u002F2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors","ODIN","Inclusion Criteria:\n\n* Must have given written informed consent\n* Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer))\n* Prior treatment with at least one line of cytotoxic systemic therapy for metastatic\u002Funresectable cancer\n* Adult patients (≥18 years of age)\n* Must be willing to comply with study procedures\n\nExclusion Criteria:\n\n• History or presence of any clinically significant disorders as judged by the Investigator.","ALL","18 Years",{"count":81,"type":82},43,"ESTIMATED","INTERVENTIONAL",[85,86],"PHASE1","PHASE2","This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.",[89,90,91,92,93,94],"Solid Tumor","Colorectal Cancer (CRC)","Squamous Cell Carcinoma of Head and Neck","Non-Small Cell Lung Cancer (NSCLC)","Gastrooesophageal Junction Cancer","Gastric Cancer","2026-01-27",{"date":97,"type":98},"2026-01-28","ACTUAL",{"date":100,"type":98},"2025-08-22",{"date":102,"type":82},"2026-12",{"name":104,"class":6},"One-carbon Therapeutics AB",4]